Radius Health Inc (RDUS) 57.80 $RDUS
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - 1 hr 14 mins ago
It's government shutdown season and that's never good for the stock market, Cramer says. So he'll be watching Washington as well as earnings from Johnson & Johnson and Wells Fargo.
GE: 28.07 (+0.04), HON: 101.16 (+0.09), DAL: 47.21 (+1.25), C: 51.38 (-0.27), PSTG: 16.60 (+0.67), QSII: 12.54 (+0.11), INTC: 32.14 (-0.38), SLB: 76.36 (-0.28), JNJ: 95.37 (+0.29), T: 33.14 (-0.26), ETP: 46.39 (+0.91), JPM: 61.93 (-0.20), GWPH: 87.75 (+0.45), HSIC: 141.70 (+0.51), GLNG: 32.01 (-1.47), LNG: 53.04 (-0.25), WFC: 52.14 (-0.40), BAC: 15.58 (-0.17), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), CSX: 29.08 (-0.01), CI: 136.36 (+2.73), RDUS: 57.80 (-3.30), WBA: 85.37 (+1.09), GS: 179.19 (-1.88), VZ: 44.16 (-0.07)
'Mad Money' Lightning Round: IBM Is Getting Attractive
at The Street - Fri Sep 25, 5:00AM CDT
Cramer says Radius Health is terrific but Blue Buffalo Pet Products is expensive compared to its growth rate.
RDUS: 57.80 (-3.30),
71.02 (+0.31), YHOO: 32.52 (+0.15), CY: 9.20 (-0.14), WTR: 27.13 (+0.05), SNR: 11.47 (-0.03), IBM: 152.39 (+0.11), ED: 65.43 (-0.84), HUN: 12.75 (-0.52), BUFF: 18.73 (+0.51), BABA: 68.71 (+1.01)
Jim Cramer's 'Mad Money' Recap: Don't Take It Personal but Your Stocks Are Going Down
at The Street - Thu Sep 24, 6:57PM CDT
It's not that you haven't picked great stocks, the market just stinks and is acting irrationally, Cramer confides.
71.02 (+0.31), CY: 9.20 (-0.14), CCL: 49.36 (-0.26), ED: 65.43 (-0.84), LLY: 86.14 (+2.37), TKR: 30.99 (-0.01), BA: 139.70 (+0.66), HUN: 12.75 (-0.52), BUFF: 18.73 (+0.51), DRI: 66.68 (-0.08), RDUS: 57.80 (-3.30), YHOO: 32.52 (+0.15), WTR: 27.13 (+0.05), TMST: 14.59 (+0.33), AZO: 736.92 (+1.61), SNR: 11.47 (-0.03), OPK: 8.90 (+0.26), IBM: 152.39 (+0.11), MRK: 50.95 (-0.07), CAT: 71.30 (-0.54), BABA: 68.71 (+1.01)
Radius Health, Inc. Announces Webcast on Investigational Drug RAD1901, Upcoming Presentations and Investor Day in New York City on November 17th, 2015
GlobeNewswire - Tue Sep 22, 4:13PM CDT
Radius Health, Inc. ("Radius" or the "Company"
(Nasdaq:RDUS) announced today that it plans to host a conference call and webcast on Thursday, September 24, 2015, to provide an update on the safety and tolerability profile of RAD1901, a selective estrogen receptor degrader, from the completed Phase I study of RAD1901 in 52 healthy volunteers.
RDUS: 57.80 (-3.30)
Biotechnology Equities under Review -- Radius Health, Hemispherx Biopharma, Seattle Genetics, Spectrum Pharma and Vanda Pharma
PR Newswire - Tue Sep 15, 7:40AM CDT
Equity Research Institute has initiated coverage on the following equities: Radius Health Inc. (NASDAQ: RDUS), Hemispherx Biopharma Inc. (AMEX: HEB), Seattle Genetics Inc. (NASDAQ: SGEN), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research report on Radius Health can be accessed at https://www.erionline.net/reports?keyword=RDUS. On Monday, September 14, 2015, the NASDAQ Composite ended at 4,805.76, down 0.34%, the Dow Jones Industrial Average edged 0.38% lower, to finish the day at 16,370.96 and the S&P 500 closed at 1,953.03, down 0.41%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
RDUS: 57.80 (-3.30), SGEN: 39.38 (+0.87), HEB: 0.16 (unch), VNDA: 10.98 (-0.04), SPPI: 6.20 (+0.07)
Radius Health Announced That it Has Appointed Catherine Friedman to the Board of Directors
GlobeNewswire - Tue Aug 18, 6:00AM CDT
Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer, today announced that Catherine Friedman, an independent consultant and former Co-Head of the Biotechnology Practice at Morgan Stanley, has been elected to its Board of Directors. Cathy has also been appointed Chair of the Audit Committee of the Board of Directors, replacing Dr. Muenchbach, who has resigned from the Board effective November 3, 2015, but will remain on the Board until that date in order to ensure a smooth transition.
RDUS: 57.80 (-3.30)
Jim Cramer's Top Takeaways: Radius Health, Inovio Pharmaceuticals
at The Street - Tue Aug 11, 5:00AM CDT
Cramer says Radius Health offers investors multiple ways to win.
RDUS: 57.80 (-3.30), INO: 6.16 (+0.20), AZN: 32.23 (-0.16)
'Mad Money' Lightning Round: Buy, Buy, Buy MGM Resorts
at The Street - Tue Aug 11, 5:00AM CDT
Cramer likes Enterprise Products Partners, says Dave and Busters is in a tough business and thinks Helen of Troy should be higher.
RDUS: 57.80 (-3.30), HELE: 101.72 (+6.96), PLAY: 39.84 (-0.92), MGM: 21.23 (+0.09), MDXG: 9.40 (+0.01), EPD: 28.78 (+0.24)
Jim Cramer's 'Mad Money' Recap: 10 Things That Created Today's Market Rally
at The Street - Mon Aug 10, 7:23PM CDT
Warren Buffett was one reason for the rally, Cramer says. Here are nine more.
SNA: 161.89 (+0.17), L: 36.29 (-0.49), XOM: 79.26 (-0.77), CB: 125.21 (+0.07), PCP: 230.31 (+0.01), ETR: 67.56 (-0.11), INO: 6.16 (+0.20), DO: 20.32 (+0.15), AMAT: 15.65 (-0.02), GOOGL: 671.24 (+4.24), HSIC: 141.70 (+0.51), AAPL: 112.12 (+2.62), MDXG: 9.40 (+0.01), SE: 29.85 (-0.53), MGM: 21.23 (+0.09), WWAV: 43.82 (+2.11), HELE: 101.72 (+6.96), NFLX: 113.33 (-1.60), RDUS: 57.80 (-3.30), AA: 10.26 (-0.75), LEN: 51.33 (+0.26), AZN: 32.23 (-0.16), PLAY: 39.84 (-0.92), PG: 74.48 (+0.08), GIS: 56.61 (+0.13), EPD: 28.78 (+0.24)
Radius Health Q2 Loss Wider than Expected, Narrower Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 5:21PM CDT
Radius Health (RDUS) reported a loss of 61 cents per share in the second-quarter of 2015, wider than the Zacks Consensus Estimate of a loss of 50 cents.
RDUS: 57.80 (-3.30), VRX: 175.94 (+4.77), ANAC: 115.06 (+2.13), CORT: 3.74 (-0.05)
Radius Health (RDUS) Posts Wider-Than-Expected Q2 Loss - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 6:46AM CDT
Radius Health (RDUS) Posts Wider-Than-Expected Q2 Loss
RDUS: 57.80 (-3.30)
Radius Health Reports Second Quarter 2015 Financial and Operating Results
GlobeNewswire - Thu Aug 06, 5:00AM CDT
-- Management to host conference call today at 7:30 am EDT
RDUS: 57.80 (-3.30)
Radius Health to Present at the 35th Annual Canaccord Genuity Growth Conference
GlobeNewswire - Wed Aug 05, 7:52PM CDT
Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including metastatic breast cancer, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the 35th Annual Canaccord Genuity Growth Conference on August 12, 2015 at 3:30 pm EDT at the Intercontinental Hotel in Boston, MA.
RDUS: 57.80 (-3.30)
Will Radius Health (RDUS) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 04, 12:30PM CDT
Radius Health (RDUS) has an Earnings ESP of -6.00% with a Zacks Rank #2 and is scheduled to report its second-quarter 2015 results on Aug 6.
RDUS: 57.80 (-3.30), INO: 6.16 (+0.20), MYL: 42.55 (-0.12), EPZM: 13.66 (-0.34)
Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030
PR Newswire - Thu Jul 30, 6:32PM CDT
INTRODUCTIONTransdermal delivery via microneedles is increasingly gaining traction as one of the more promising drug delivery technologies. Microneedles are of a few hundred microns in size, capable of creating transient pores across the skin by penetrating the stratum corneum layer to deliver molecules. These needles are not big enough to reach the nerve-rich regions of the skin; as a result, the drug delivery is perceived as completely painless and devoid of bleeding. Drugs, vaccines, proteins, peptides and other biomolecules are suitable for delivery using the microneedle technology.
RDUS: 57.80 (-3.30)
Radius Health to Announce Second Quarter 2015 Financial Results, Host Conference Call and Live Webcast on August 6, 2015
GlobeNewswire - Thu Jul 30, 7:01AM CDT
Radius Health (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, announced today that it will release its second quarter 2015 financial results on Thursday, August 6, 2015.
RDUS: 57.80 (-3.30)
5 Stocks Insiders Love Right Now
at The Street - Wed Jul 29, 7:14AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
RDUS: 57.80 (-3.30), ZINC: 5.51 (+1.05), BIIB: 269.16 (-10.72), MJN: 72.03 (-0.10), DPZ: 105.38 (+2.74)
Radius Health, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Jul 28, 3:30PM CDT
Radius Health, Inc. (NASDAQ:RDUS), a science-driven biopharmaceutical company focused on developing potential new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, today announced the closing of its previously announced public offering of 4,662,162 shares of common stock at a public offering price of $74.00 per share, including 608,108 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares of common stock.
RDUS: 57.80 (-3.30), JPM: 61.93 (-0.20), DB: 29.34 (+0.95)
Radius Health Announces That it Has Hired Dr. Lorraine Fitzpatrick, Former GlaxoSmithKline Development Leader for Denosumab, as Chief Medical Officer
GlobeNewswire - Mon Jul 27, 4:28PM CDT
Radius Health, Inc. (NASDAQ:RDUS) (the "Company" , a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer, today announced that it has hired Dr. Lorraine A. Fitzpatrick as Chief Medical Officer of the Company. Dr. Fitzpatrick was previously Medicine Development Leader of an international clinical development team for Denosumab at GlaxoSmithKline, responsible for clinical development, regulatory, manufacturing, commercial, operations, epidemiology, and global health outcomes. Previously, Dr. Fitzpatrick led the clinical development of novel agents to treat musculoskeletal diseases and women's health at GlaxoSmithKline. Before joining GlaxoSmithKline, Dr. Fitzpatrick was Executive Director at Amgen, Inc. where she worked in the fields of osteoporosis and oncology.
RDUS: 57.80 (-3.30), GSK: 40.22 (+0.06)
Radius Health, Inc. Announces Pricing of Public Offering
GlobeNewswire - Wed Jul 22, 7:03PM CDT
Radius Health, Inc. (NASDAQ:RDUS) (the "Company" , a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, today announced that it has priced its public offering of 4,054,054 shares of its common stock at a public offering price of $74.00 per share. In addition, the Company has granted the underwriters an option to purchase up to an additional 608,108 shares of its common stock, exercisable for 30 days.
RDUS: 57.80 (-3.30), JPM: 61.93 (-0.20), DB: 29.34 (+0.95)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - 1 hr 14 mins ago
It's government shutdown season and that's never good for the stock market, Cramer says. So he'll be watching Washington as well as earnings from Johnson & Johnson and Wells Fargo.
GE: 28.07 (+0.04), HON: 101.16 (+0.09), DAL: 47.21 (+1.25), C: 51.38 (-0.27), PSTG: 16.60 (+0.67), QSII: 12.54 (+0.11), INTC: 32.14 (-0.38), SLB: 76.36 (-0.28), JNJ: 95.37 (+0.29), T: 33.14 (-0.26), ETP: 46.39 (+0.91), JPM: 61.93 (-0.20), GWPH: 87.75 (+0.45), HSIC: 141.70 (+0.51), GLNG: 32.01 (-1.47), LNG: 53.04 (-0.25), WFC: 52.14 (-0.40), BAC: 15.58 (-0.17), LLY: 86.14 (+2.37), BMY: 61.44 (+0.93), CSX: 29.08 (-0.01), CI: 136.36 (+2.73), RDUS: 57.80 (-3.30), WBA: 85.37 (+1.09), GS: 179.19 (-1.88), VZ: 44.16 (-0.07)
'Mad Money' Lightning Round: IBM Is Getting Attractive
at The Street - Fri Sep 25, 5:00AM CDT
Cramer says Radius Health is terrific but Blue Buffalo Pet Products is expensive compared to its growth rate.
RDUS: 57.80 (-3.30),
71.02 (+0.31), YHOO: 32.52 (+0.15), CY: 9.20 (-0.14), WTR: 27.13 (+0.05), SNR: 11.47 (-0.03), IBM: 152.39 (+0.11), ED: 65.43 (-0.84), HUN: 12.75 (-0.52), BUFF: 18.73 (+0.51), BABA: 68.71 (+1.01) Jim Cramer's 'Mad Money' Recap: Don't Take It Personal but Your Stocks Are Going Down
at The Street - Thu Sep 24, 6:57PM CDT
It's not that you haven't picked great stocks, the market just stinks and is acting irrationally, Cramer confides.
71.02 (+0.31), CY: 9.20 (-0.14), CCL: 49.36 (-0.26), ED: 65.43 (-0.84), LLY: 86.14 (+2.37), TKR: 30.99 (-0.01), BA: 139.70 (+0.66), HUN: 12.75 (-0.52), BUFF: 18.73 (+0.51), DRI: 66.68 (-0.08), RDUS: 57.80 (-3.30), YHOO: 32.52 (+0.15), WTR: 27.13 (+0.05), TMST: 14.59 (+0.33), AZO: 736.92 (+1.61), SNR: 11.47 (-0.03), OPK: 8.90 (+0.26), IBM: 152.39 (+0.11), MRK: 50.95 (-0.07), CAT: 71.30 (-0.54), BABA: 68.71 (+1.01) Radius Health, Inc. Announces Webcast on Investigational Drug RAD1901, Upcoming Presentations and Investor Day in New York City on November 17th, 2015
GlobeNewswire - Tue Sep 22, 4:13PM CDT
Radius Health, Inc. ("Radius" or the "Company"
(Nasdaq:RDUS) announced today that it plans to host a conference call and webcast on Thursday, September 24, 2015, to provide an update on the safety and tolerability profile of RAD1901, a selective estrogen receptor degrader, from the completed Phase I study of RAD1901 in 52 healthy volunteers. RDUS: 57.80 (-3.30)
Biotechnology Equities under Review -- Radius Health, Hemispherx Biopharma, Seattle Genetics, Spectrum Pharma and Vanda Pharma
PR Newswire - Tue Sep 15, 7:40AM CDT
Equity Research Institute has initiated coverage on the following equities: Radius Health Inc. (NASDAQ: RDUS), Hemispherx Biopharma Inc. (AMEX: HEB), Seattle Genetics Inc. (NASDAQ: SGEN), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free research report on Radius Health can be accessed at https://www.erionline.net/reports?keyword=RDUS. On Monday, September 14, 2015, the NASDAQ Composite ended at 4,805.76, down 0.34%, the Dow Jones Industrial Average edged 0.38% lower, to finish the day at 16,370.96 and the S&P 500 closed at 1,953.03, down 0.41%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.
RDUS: 57.80 (-3.30), SGEN: 39.38 (+0.87), HEB: 0.16 (unch), VNDA: 10.98 (-0.04), SPPI: 6.20 (+0.07)
Radius Health Announced That it Has Appointed Catherine Friedman to the Board of Directors
GlobeNewswire - Tue Aug 18, 6:00AM CDT
Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer, today announced that Catherine Friedman, an independent consultant and former Co-Head of the Biotechnology Practice at Morgan Stanley, has been elected to its Board of Directors. Cathy has also been appointed Chair of the Audit Committee of the Board of Directors, replacing Dr. Muenchbach, who has resigned from the Board effective November 3, 2015, but will remain on the Board until that date in order to ensure a smooth transition.
RDUS: 57.80 (-3.30)
Jim Cramer's Top Takeaways: Radius Health, Inovio Pharmaceuticals
at The Street - Tue Aug 11, 5:00AM CDT
Cramer says Radius Health offers investors multiple ways to win.
RDUS: 57.80 (-3.30), INO: 6.16 (+0.20), AZN: 32.23 (-0.16)
'Mad Money' Lightning Round: Buy, Buy, Buy MGM Resorts
at The Street - Tue Aug 11, 5:00AM CDT
Cramer likes Enterprise Products Partners, says Dave and Busters is in a tough business and thinks Helen of Troy should be higher.
RDUS: 57.80 (-3.30), HELE: 101.72 (+6.96), PLAY: 39.84 (-0.92), MGM: 21.23 (+0.09), MDXG: 9.40 (+0.01), EPD: 28.78 (+0.24)
Jim Cramer's 'Mad Money' Recap: 10 Things That Created Today's Market Rally
at The Street - Mon Aug 10, 7:23PM CDT
Warren Buffett was one reason for the rally, Cramer says. Here are nine more.
SNA: 161.89 (+0.17), L: 36.29 (-0.49), XOM: 79.26 (-0.77), CB: 125.21 (+0.07), PCP: 230.31 (+0.01), ETR: 67.56 (-0.11), INO: 6.16 (+0.20), DO: 20.32 (+0.15), AMAT: 15.65 (-0.02), GOOGL: 671.24 (+4.24), HSIC: 141.70 (+0.51), AAPL: 112.12 (+2.62), MDXG: 9.40 (+0.01), SE: 29.85 (-0.53), MGM: 21.23 (+0.09), WWAV: 43.82 (+2.11), HELE: 101.72 (+6.96), NFLX: 113.33 (-1.60), RDUS: 57.80 (-3.30), AA: 10.26 (-0.75), LEN: 51.33 (+0.26), AZN: 32.23 (-0.16), PLAY: 39.84 (-0.92), PG: 74.48 (+0.08), GIS: 56.61 (+0.13), EPD: 28.78 (+0.24)
Radius Health Q2 Loss Wider than Expected, Narrower Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 07, 5:21PM CDT
Radius Health (RDUS) reported a loss of 61 cents per share in the second-quarter of 2015, wider than the Zacks Consensus Estimate of a loss of 50 cents.
RDUS: 57.80 (-3.30), VRX: 175.94 (+4.77), ANAC: 115.06 (+2.13), CORT: 3.74 (-0.05)
Radius Health (RDUS) Posts Wider-Than-Expected Q2 Loss - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Aug 06, 6:46AM CDT
Radius Health (RDUS) Posts Wider-Than-Expected Q2 Loss
RDUS: 57.80 (-3.30)
Radius Health Reports Second Quarter 2015 Financial and Operating Results
GlobeNewswire - Thu Aug 06, 5:00AM CDT
-- Management to host conference call today at 7:30 am EDT
RDUS: 57.80 (-3.30)
Radius Health to Present at the 35th Annual Canaccord Genuity Growth Conference
GlobeNewswire - Wed Aug 05, 7:52PM CDT
Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including metastatic breast cancer, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the 35th Annual Canaccord Genuity Growth Conference on August 12, 2015 at 3:30 pm EDT at the Intercontinental Hotel in Boston, MA.
RDUS: 57.80 (-3.30)
Will Radius Health (RDUS) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 04, 12:30PM CDT
Radius Health (RDUS) has an Earnings ESP of -6.00% with a Zacks Rank #2 and is scheduled to report its second-quarter 2015 results on Aug 6.
RDUS: 57.80 (-3.30), INO: 6.16 (+0.20), MYL: 42.55 (-0.12), EPZM: 13.66 (-0.34)
Microneedles for Transdermal and Intradermal Drug Delivery, 2014-2030
PR Newswire - Thu Jul 30, 6:32PM CDT
INTRODUCTIONTransdermal delivery via microneedles is increasingly gaining traction as one of the more promising drug delivery technologies. Microneedles are of a few hundred microns in size, capable of creating transient pores across the skin by penetrating the stratum corneum layer to deliver molecules. These needles are not big enough to reach the nerve-rich regions of the skin; as a result, the drug delivery is perceived as completely painless and devoid of bleeding. Drugs, vaccines, proteins, peptides and other biomolecules are suitable for delivery using the microneedle technology.
RDUS: 57.80 (-3.30)
Radius Health to Announce Second Quarter 2015 Financial Results, Host Conference Call and Live Webcast on August 6, 2015
GlobeNewswire - Thu Jul 30, 7:01AM CDT
Radius Health (Nasdaq:RDUS), a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers, announced today that it will release its second quarter 2015 financial results on Thursday, August 6, 2015.
RDUS: 57.80 (-3.30)
5 Stocks Insiders Love Right Now
at The Street - Wed Jul 29, 7:14AM CDT
Insiders at these companies have been scooping up shares of their own stock lately.
RDUS: 57.80 (-3.30), ZINC: 5.51 (+1.05), BIIB: 269.16 (-10.72), MJN: 72.03 (-0.10), DPZ: 105.38 (+2.74)
Radius Health, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Jul 28, 3:30PM CDT
Radius Health, Inc. (NASDAQ:RDUS), a science-driven biopharmaceutical company focused on developing potential new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, today announced the closing of its previously announced public offering of 4,662,162 shares of common stock at a public offering price of $74.00 per share, including 608,108 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares of common stock.
RDUS: 57.80 (-3.30), JPM: 61.93 (-0.20), DB: 29.34 (+0.95)
Radius Health Announces That it Has Hired Dr. Lorraine Fitzpatrick, Former GlaxoSmithKline Development Leader for Denosumab, as Chief Medical Officer
GlobeNewswire - Mon Jul 27, 4:28PM CDT
Radius Health, Inc. (NASDAQ:RDUS) (the "Company"
, a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer, today announced that it has hired Dr. Lorraine A. Fitzpatrick as Chief Medical Officer of the Company. Dr. Fitzpatrick was previously Medicine Development Leader of an international clinical development team for Denosumab at GlaxoSmithKline, responsible for clinical development, regulatory, manufacturing, commercial, operations, epidemiology, and global health outcomes. Previously, Dr. Fitzpatrick led the clinical development of novel agents to treat musculoskeletal diseases and women's health at GlaxoSmithKline. Before joining GlaxoSmithKline, Dr. Fitzpatrick was Executive Director at Amgen, Inc. where she worked in the fields of osteoporosis and oncology. RDUS: 57.80 (-3.30), GSK: 40.22 (+0.06)
Radius Health, Inc. Announces Pricing of Public Offering
GlobeNewswire - Wed Jul 22, 7:03PM CDT
Radius Health, Inc. (NASDAQ:RDUS) (the "Company"
, a science-driven biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive metastatic breast cancer, today announced that it has priced its public offering of 4,054,054 shares of its common stock at a public offering price of $74.00 per share. In addition, the Company has granted the underwriters an option to purchase up to an additional 608,108 shares of its common stock, exercisable for 30 days. RDUS: 57.80 (-3.30), JPM: 61.93 (-0.20), DB: 29.34 (+0.95)
